Showing results (111-120 of 147) with videos related to
Sort By:
Pageof 15
Histopathology|March 6, 2012
High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancerFrederick Klauschen, Moritz von Winterfeld, Albrecht Stenzinger, et al.The Oncologist|April 14, 2018
Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or VomitingHanno Riess, Cihan Ay, Rupert Bauersachs, et al.Intensive Care Medicine|April 25, 2003
Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trialJean-François Dhainaut, Pierre-François Laterre, Jonathan M Janes, et al.Journal of Surgical Oncology|September 17, 2013
Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 studyMarianne Sinn, Jana K Striefler, Bruno V Sinn, et al.Annals of Surgical Oncology|April 4, 2021
Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic AdenocarcinomaMichele Reni, Julia Braverman, Andrew Hendifar, et al.Pancreas|March 6, 2020
Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature ReviewTeresa Macarulla, Andrew E Hendifar, Chung-Pin Li, et al.Blood Cells, Molecules & Diseases|February 25, 2005
Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptorMatthias Holdhoff, Karl-Anton Kreuzer, Christine Appelt, et al.Thrombosis and Haemostasis|September 30, 2003
Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsisJean-François Dhainaut, S Betty Yan, Benjamin D Margolis, et al.European Journal of Cancer (Oxford, England : 1990)|August 4, 2017
Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinomaPhilipp Lohneis, Marianne Sinn, Sven Bischoff, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2014
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trialHelmut Oettle, Hanno Riess, Jens M Stieler, et al.Pageof 15